Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 8Recruiting 3Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Surveys and Questionnaires 9Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Induction Chemotherapy × Head & Neck × Clear all
NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Sun Yat-sen University

Phase 3 Active not recruiting
452 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡